Drug Type Small molecule drug |
Synonyms 2-Actamido-2-deoxy-D-mannose, D-ManNAc, LB-301 - Leadiant Biosciences + [7] |
Target- |
Mechanism Glycosylation stimulants, Proteins modulators |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC8H15NO6 |
InChIKeyMBLBDJOUHNCFQT-WCTZXXKLSA-N |
CAS Registry3615-17-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Distal Myopathies | Phase 3 | - | - | |
Distal Myopathies | Phase 3 | - | - | |
Glomerulosclerosis, Focal Segmental | Phase 2 | US | 26 Nov 2024 | |
Distal Myopathy, Nonaka Type | Phase 2 | US | 05 Feb 2015 | |
Kidney Diseases | Phase 1 | US | 07 Jul 2016 |
Phase 2 | 12 | pvamkoghop(brgfpkxkqp) = kebvuderjs criilsrmvt (nbceekhscn ) | Positive | 01 Nov 2021 | |||
Phase 1 | 7 | ManNAc 3g single dose | zszplskpgp(ddnoukkisq) = There were no serious adverse events. Most subjects (5 of 6) that received ManNAc twice daily showed a marked reduction in urine PCR (26-54%), which correlated with the degree of glomerular hyposialylation klciloazne (zmnwcoqbwv ) View more | Positive | 19 Oct 2020 | ||
Phase 2 | 12 | (ManNAc: Cohort A) | lzeovwnqxu(nhrmmckmmz) = ozatjcunef noytantvor (knkyffhnxc, mfbkqzwazz - retwldjtgo) View more | - | 16 Apr 2019 | ||
(ManNAc: Cohort B) | lzeovwnqxu(nhrmmckmmz) = pogrxrylqx noytantvor (knkyffhnxc, phtlhtlefe - qxuzbtzggl) View more | ||||||
Not Applicable | Nephrosis, Lipoid Angptl4 | NPHS2-Angptl4 | PAN | - | bqlmeuvumn(bbaitgzjmm) = ihvklexvik afntvqborm (eawmzieift ) | Positive | 16 Nov 2010 |